公开(公告)号：EP3367890A1

公开(公告)日：2018-09-05

申请号：EP16860690.3

申请日：2016-10-26

申请人： Immunolight, LLC. ,  Duke University

发明人： OLDHAM, Mark ,  ADAMSON, Justus ,  DEWHIRST, Mark, W. ,  YOON, Paul ,  WALDER, Harold ,  BOURKE, Frederic, A. ,  FATHI, Zakaryae ,  BEYER, Wayne, F.

IPC分类号： A61B5/00 ,  A61K33/02 ,  A61K41/00 ,  A61K49/04 ,  A61M36/02 ,  A61N5/06 ,  A61N5/10

CPC分类号： A61K41/0066 ,  A61K31/352 ,  A61K31/403 ,  A61K31/409 ,  A61K31/426 ,  A61K31/47 ,  A61K31/525 ,  A61K31/655 ,  A61K33/02 ,  A61K33/24 ,  A61K2300/00 ,  A61N5/062 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/065 ,  A61N2005/1095 ,  A61N2005/1098 ,  B82Y5/00 ,  Y02A50/393

摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

公开(公告)号：EP3630283A1

公开(公告)日：2020-04-08

申请号：EP18810795.7

申请日：2018-05-31

申请人： Immunolight, LLC ,  Duke University

发明人： BOURKE, Frederic A. ,  DEWHIRST, Mark ,  SPECTOR, Neil ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya ,  OLDHAM, Mark ,  FATHI, Zakaryae ,  BEYER, Wayne F. ,  WALDER, Harold

IPC分类号： A61N5/06 ,  A61B6/00 ,  A61K9/00 ,  A61K49/04 ,  A61N5/10

公开(公告)号：EP3411119A1

公开(公告)日：2018-12-12

申请号：EP17748119.9

申请日：2017-02-02

申请人： Immunolight, LLC. ,  Duke University ,  North Carolina State University

发明人： WALDER, Harold ,  BOURKE, Frederic A., Jr. ,  FATHI, Zakaryae ,  BEYER, Wayne ,  OLDHAM, Mark ,  ADAMSON, Justus ,  NOLAN, Michael

IPC分类号： A61N5/10 ,  A61K41/00 ,  A61K49/04

CPC分类号： A61N5/10 ,  A61K41/0066 ,  A61N5/062 ,  A61N2005/0661 ,  A61N2005/1098

摘要： A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+and (3Ca3 (PO4)2Ca(F, CI)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

公开(公告)号：EP3365017A1

公开(公告)日：2018-08-29

申请号：EP16858126.2

申请日：2016-10-19

申请人： Immunolight, LLC ,  Duke University

发明人： FATHI, Zakaryae ,  BAYER, Wayne, F. ,  WALDER, Harold ,  BOURKE, Frederic, A. ,  OLDHAM, Mark ,  DEWHIRST, Mark ,  SPECTOR, Neil, L. ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya

IPC分类号： A61K41/00

CPC分类号： A61K41/0057 ,  A61K33/42 ,  A61K41/0066 ,  A61N5/00 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/1098

摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：EP3134122A1

公开(公告)日：2017-03-01

申请号：EP15783728.7

申请日：2015-04-22

申请人： Immunolight, LLC. ,  Duke University ,  North Carolina State University

发明人： WALDER, Harold ,  BOURKE, Frederic, A. ,  FATHI, Zakaryae ,  BEYER, Wayne, F. ,  DEWHIRST, Mark, W. ,  OLDHAM, Mark ,  ADAMSON, Justus ,  NOLAN, Michael

IPC分类号： A61K41/00 ,  A61N5/06 ,  A61N5/10

CPC分类号： A61N5/062 ,  A61K41/0042 ,  A61K41/0057 ,  A61K49/0423 ,  A61N5/1071 ,  A61N2005/1089 ,  A61N2005/1091 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x- ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x- rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

摘要翻译： 介质内光刺激的系统和方法。 该系统具有被配置为从等于或低于200kVp的施加阴极施加电压产生X射线的降低电压x射线源，以及介质中的多个能量转换粒子，其在来自X射线源的辐射 以比x射线源低的能量辐射以与介质中的至少一种可光活化剂相互作用。 该方法将多个能量转换粒子引入到介质中，用从200kVp以下的施加阴极电压产生的x射线照射介质中的能量转换粒子; 并且发射比x射线源更低的能量以与介质或介质中的至少一种可光活化剂相互作用。